Retevmo (selpercatinib)

pCPA File Number: 21931
Negotiation Status:
Under consideration for negotiation
Indication(s):
monotherapy treatment of rearranged during transfection (RET) fusion-positive differentiated thyroid carcinoma (DTC) in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib
Sponsor/Manufacturer:
Eli Lilly Canada Inc.
CADTH Project Number:
PC0274
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable